Astrocyte Pharmaceuticals Awarded $3M NIH Small Business Grant to Advance TBI and Concussion Therapeutic
Cambridge, MA, September 19, 2018 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, announced today that it has been awarded a $3 million Phase 2 Small Business Innovation Research (SBIR) Grant from the National Institute Of Neurological Disorders And Stroke (NINDS) of the National Institutes of Health (NIH). The grant provides funding to advance […]
Cambridge, MA, September 18, 2018 – Astrocyte Pharmaceuticals, Inc., a privately held pharmaceutical company, announced today that it has been awarded $287k Phase 1 Small Business Technology Transfer (STTR) Grant from the National Institutes of Health’s (NIH) National Institute On Aging (NIA). The grant provides funding to further evaluate and advance its promising neuroprotectant drug […]
Cambridge, MA, June 6, 2018 – Astrocyte Pharmaceuticals Inc. announced today that it has completed a Pre-A financing round that raised over $2.3M. The company is advancing several small molecule neuroprotective therapeutics for the treatment of stroke, traumatic brain injury (TBI) or concussion, and neurodegenerative disease. The Pre-A round was led by Kaitai Capital, and […]
In the Media
“To Curb Brain Damage, Astrocyte Pharmaceuticals Energizes Cells” article in Xconomy by David Holley.
Company Profile published by Nature Biopharma Dealmakers in the September 2015 issue dedicated to Neuroscience companies and their research.
- The full issue can be viewed here.
- The Astrocyte Pharmaceuticals profile page is here: Nature Biopharma Dealmakers – Astrocyte Pharmaceuticals Profile. Sept. 2015.
Coverage by International Innovation in the May 20th 2014 issue (Issue 142), “A Brainy Bunch” (free registration required)